Skip to main content

Table 1 Characteristics of study population

From: MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

  Training cohort (N = 39) Validation cohort (N = 39)
Age, years – median [range] 62 [54–70] 66 [61–72]
Gender - N(%)   
Male 23 (59.0%) 29 (74.4%)
Female 16 (41.0%) 10 (25.6%)
Histology of primary tumor - N(%)   
Adenocarcinoma 35 (89.7%) 39 (100%)
Mucinous adenocarcinoma 4 (10.3%) -
Chemotherapy regimen - N(%)   
Ox/FP regimens 30 (76.9%) 29 (74.3%)
Ir/FP regimens 7 (17.9%) 9 (23.1%)
FP monotherapy 2 (5.2%) 1 (2.6%)
Response to chemotherapy - N(%)   
Objective Response (CR, PR) 18 (46.2%) 24 (61.5%)
No Response (SD, PD) 21 (53.8%) 15 (38.5%)
Survival, months – median [range]   
Progression-free survival 12.2 [6.3-18.9] 11.6 [8.6-18.3]
Overall survival 24.6 [15.8-37.2] 21.5 [13.3-31.1]
  1. Continuous variables are expressed as median [interquartile range (IQR)] and categorical variables as number of cases (%). Ox: oxaliplatin; FP: fluoropyrimidine; Ir: Irinotecan. CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.